Research programme: stem cell therapies - Cytovis

Drug Profile

Research programme: stem cell therapies - Cytovis

Alternative Names: CytoCor; CytoRet

Latest Information Update: 02 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator International Stem Cell Corporation
  • Developer Cytovis; University of California at Irvine
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Corneal disorders; Retinal disorders

Most Recent Events

  • 31 Oct 2017 International Stem Cell Corporation receives patent allowance for methods for generating HLA homozygous parthenogenetic human stem cell lines in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Corneal-disorders in USA (Intraocular, Implant)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intraocular, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top